CompanyBioInvent International AB
Sweden
BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical need. The companyÂ’s strategy is to leverage its expertise in antibodies and cancer biology to develop immuno-oncology drugs that significantly improve the treatment of cancer diseases and prolong cancer patients' lives.
Private/Public:
public
Phone:+46 (0)46-286 85 50
Fax:+46 (0)46-211 08 06
Email:[email protected]
Website:http://www.bioinvent.com/
Address:Ideon Science Park SE-223 70 Lund, Sweden
1996
Since
1
Country
7
Top Service Categories
62
Sub-Service Categories
Top Services
Analytical
Analytical lab services
Discovery and Preclinical
Specific Services-Discovery
Microbiology
Specific Services - microbiology
API/Biologicals Production
Small mol. API/Biologic products production
Formulation
Formulation Process Capabilities
Formulation Type
Bioanalytical
Bioanalytical assays
Sweden
- (08.Nov.2019) BioInvent to Present BI-1206 Preclinical Data in Mantle Cell Lymphoma at ASH 2019
- (24.Oct.2019) Interim Report January 1 – September 30, 2019
- (23.Oct.2019) BioInvent Signs Manufacturing Agreement With Cancer Research UK Expected to Generate Approximately SEK 30 Million (~$3 Million)
- (22.Aug.2019) BioInvent: Interim Report January 1 - June 30, 2019
- (21.Aug.2019) BioInvent Will Conduct Phase I/IIa Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors
- (20.Aug.2019) Oxurion NV Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (Anti-Plgf), in Combination With Ranibizumab, for DME
- (15.Aug.2019) USPTO Intends to Grant BioInvent Patent Relating to BI-1206
- (31.Jul.2019) BioInvent Announces Selection of First Target Discovered by BioInvent's Proprietary F.I.R.S.T Technology Platform Under Collaboration With Pfizer Inc
- (04.Jul.2019) BioInvent Receives Milestone Payment Related to TAK-169 Investigational New Drug Application
- (02.Jul.2019) Bioinvent Receives Ind Approval for Phase I/IIa Trial of Anti-Fcγriib Antibody
- (28.Jun.2019) Change in the Number of Shares and Votes in BioInvent International AB
- (12.Jun.2019) BioInvent Publishes First Clinical Data From BI-1206 Phase I/IIa Trials
- (03.Jun.2019) BioInvent Submits IND for Phase I/IIa Trial of Anti-FcγRIIB Antibody
- (22.May.2019) BioInvent Interim Report January 1 - March 31, 2019
- (26.Apr.2019) BioInvent Receives EUR0.75 Million Milestone Under Mitsubishi Tanabe Pharma Partnership
- (26.Mar.2019) Transgene and BioInvent Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
- (21.Mar.2019) BioInvent Unveils Broad Anti-Tnfr2 Program to Treat Solid Tumors
- (19.Mar.2019) Notice to Annual General Meeting in BioInvent International AB
- (13.Mar.2019) BioInvent Expands U.S. Patent Protection for Its F.I.R.S.T. Platform
- (12.Mar.2019) BioInvent Announces Publication of Review Article in Frontiers in Immunology on Resistance to Antibody Drugs
- (25.Feb.2019) Notice of Extraordinary General Meeting in BioInvent International AB
- (25.Feb.2019) BioInvent Financial Statement January 1 - December 31, 2018
- (25.Feb.2019) BioInvent to Advance and Expand Existing and New Development Programs Through a Fully Underwritten Rights Issue and a Directed Issue of in Total MSEK 240
- (05.Feb.2019) BioInvent CSO to Present F.I.R.S.T. Discovery Platform at SLAS2019
- (30.Jan.2019) BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma
- (20.Nov.2018) BioInvent Signs Manufacturing Agreement with U.S. Cell Therapy Company
Analytical Equipment
Manufacturing Equipment
Facility Inspection/License Status
Phone:+46 (0)46-286 85 50
Fax:+46 (0)46-211 08 06
Email:[email protected]
Website:http://www.bioinvent.com/
Address:Ideon Science Park SE-223 70 Lund
+46 (0)46-286 85 50Fax:
+46 (0)46-211 08 06Email:
[email protected]Website:
http://www.bioinvent.com/Address:
Ideon Science Park SE-223 70 Lund